U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H30O5
Molecular Weight 374.4714
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPREDNISOLONE

SMILES

C[C@@]1([H])C[C@@]2([H])[C@]3([H])CC[C@](C(=O)CO)([C@@]3(C)C[C@@]([H])([C@]2([H])[C@@]4(C)C=CC(=O)C=C14)O)O

InChI

InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H30O5
Molecular Weight 374.4714
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html

Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.

Originator

Curator's Comment:: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.4 nM [EC50]
1.07 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-3.84739213E11
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-3.84739213E11
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

-3.84739213E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
213 ng/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
931 ng × h/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23%
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/kg single, intravenous
Highest studied dose
Dose: 1000 mg/kg
Route: intravenous
Route: single
Dose: 1000 mg/kg
Sources:
unhealthy, 0-15 years
n = 26
Health Status: unhealthy
Condition: sickle cell disease
Age Group: 0-15 years
Sex: M+F
Population Size: 26
Sources:
1250 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / day
Sources:
unhealthy, 18–59 years
n = 24
Health Status: unhealthy
Condition: multiple sclerosis relapse
Age Group: 18–59 years
Sex: M+F
Population Size: 24
Sources:
120 mg 1 times / week multiple, intramuscular
Highest studied dose
Dose: 120 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 120 mg, 1 times / week
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus.
2001
Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome.
2001 Apr
Lupus nephritis in a child with AIDS.
2001 Apr
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
2001 Apr
Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults.
2001 Feb
Severe renal impairment in the case of classic polyarteritis nodosa.
2001 Feb
Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment.
2001 Feb
Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis.
2001 Feb
Steroid-resistant kidney transplant rejection: diagnosis and treatment.
2001 Feb
Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms.
2001 Feb
[Contact allergy caused by poison ivy (Toxicodendron spp].
2001 Feb
Lupus nephritis in children: prognostic significance of clinicopathological findings.
2001 Feb
[Psychological and behavioral disorders with good outcome in neurosarcoidosis].
2001 Feb
[Value of abdominal-pelvic computed tomography in adult rheumatoid purpura].
2001 Feb
Multiple corticosteroid allergies.
2001 Feb
Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study.
2001 Feb
Multiple arterial ectasias in patients with sarcoidosis and uveitis.
2001 Feb
Preliminary results of a prospective randomized study of basiliximab in kidney transplantation.
2001 Feb-Mar
Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation.
2001 Feb-Mar
Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.
2001 Feb-Mar
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation.
2001 Feb-Mar
Daclizumab induction therapy in combination with tacrolimus.
2001 Feb-Mar
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.
2001 Feb-Mar
Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.
2001 Feb-Mar
Successful withdrawal of steroid after renal transplantation.
2001 Feb-Mar
Prevention of bone loss in kidney graft recipients.
2001 Feb-Mar
Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients.
2001 Feb-Mar
Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
2001 Feb-Mar
Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion.
2001 Feb-Mar
Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue.
2001 Jan
A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease.
2001 Jan
[Severe chronic actinic dermatitis treated with cyclosporine: 2 cases].
2001 Jan
Recurrent orbital inflammation from metastatic orbital carcinoid tumor.
2001 Mar
[Intramural hematoma of the large intestine caused by cytomegalovirus vasculitis in a patient with SLE].
2001 Mar
[Value of methylprednisolone perfusions in the corticodependent forms of Horton's disease].
2001 Mar
[Acute myelitis of an unusual cause in a child: the lymphocytic choriomeningitis virus].
2001 Mar
Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
2001 Mar
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma.
2001 Mar
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
2001 Mar
Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report.
2001 Mar
Systemic glucocorticoids in severe exacerbations of COPD.
2001 Mar
Steroids for acute exacerbations of COPD : how long is enough?
2001 Mar
Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation.
2001 Mar
Effects of preoperative steroid administration on surgical stress in hepatic resection: prospective randomized trial.
2001 Mar
Spinal taurine levels are increased 7 and 30 days following methylprednisolone treatment of spinal cord injury in rats.
2001 Mar 2
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
[Comparison of two different treatments of lateral humeral epicondylitis--"tennis elbow". A randomized controlled trial].
2001 Mar 5
Prospective experience with a 20-gauge Tuohy needle for lumbar epidural steroid injections: Is confirmation with fluoroscopy necessary?
2001 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration: Other
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:19:23 UTC 2021
Edited
by admin
on Fri Jun 25 21:19:23 UTC 2021
Record UNII
X4W7ZR7023
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLPREDNISOLONE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
U-67,590A
Code English
METHYLPREDNISOLONE [USP]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-6-METHYL-, (6.ALPHA.,11.BETA.)-
Systematic Name English
METHYLPREDNISOLONE [GREEN BOOK]
Common Name English
METHYLPREDNISOLONE [EP MONOGRAPH]
Common Name English
NSC-19987
Code English
METHYLPREDNISOLONE [MI]
Common Name English
11.BETA.,17,21-TRIHYDROXY-6.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
METHYLPREDNISOLONE [MART.]
Common Name English
6-METHYL-PREDNISOLONE
Common Name English
METHYLPREDNISOLONE COMPONENT OF NEO-MEDROL
Common Name English
METHYLPREDNISOLONE [USP-RS]
Common Name English
METHYLPREDNISOLONE [ORANGE BOOK]
Common Name English
METHYLPREDNISOLONE [INN]
Common Name English
NEO-MEDROL COMPONENT METHYLPREDNISOLONE
Common Name English
J3.872E
Code English
METHYLPREDNISOLONE [JAN]
Common Name English
METHYLPREDNISOLONE [WHO-DD]
Common Name English
MEDROL
Brand Name English
6-METHYLPREDNISOLONE
Common Name English
METHYLPREDNISOLONE [VANDF]
Common Name English
METHYLPREDNISOLONE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QH02AB04
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
FDA ORPHAN DRUG 531816
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC S01CA08
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 520.1408
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07AA01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 520.1409
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD07CA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QH02BX01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
CFR 21 CFR 522.1410
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC H02BX01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QS01CA08
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07CA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D07AC14
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD10AA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-VATC QD07AA01
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC H02AB04
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
WHO-ATC D10AA02
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
LIVERTOX 626
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1768
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
MESH
D008775
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
NCI_THESAURUS
C647
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
DRUG BANK
DB00959
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
HSDB
3127
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
CAS
83-43-2
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
INN
732
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
PUBCHEM
6741
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
USP_CATALOG
1435003
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY USP-RS
IUPHAR
7088
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
EPA CompTox
83-43-2
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
RXCUI
6902
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY RxNorm
EVMPD
SUB08872MIG
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
LACTMED
Methylprednisolone
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
FDA UNII
X4W7ZR7023
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
ECHA (EC/EINECS)
201-476-4
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
ChEMBL
CHEMBL650
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
WIKIPEDIA
METHYLPREDNISOLONE
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY
MERCK INDEX
M7454
Created by admin on Fri Jun 25 21:19:23 UTC 2021 , Edited by admin on Fri Jun 25 21:19:23 UTC 2021
PRIMARY Merck Index
Related Record Type Details
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC